Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the spectrum of inherited retinal diseases.

Handbook of clinical neurology·2026
Same author

Targeting Neuroinflammation and Oxidative Stress to Slow Neurodegeneration in the Visual System.

Journal of clinical medicine·2026
Same author

Applications of Photopic Negative Response: A Narrative Review.

Journal of clinical medicine·2026
Same author

Hyperbaric Oxygen Therapy Versus Intravenous Thrombolysis in the Treatment of Central Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.

Journal of clinical medicine·2026
Same author

Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Neovascular Age-Related Macular Degeneration.

Journal of vitreoretinal diseases·2026
Same author

Visual Acuity and Durability Outcomes of Faricimab Compared With Other Anti-vascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Diabetic Macular Edema.

Journal of vitreoretinal diseases·2026

Related Experiment Video

Updated: Jul 7, 2026

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

Multifocal Electroretinography Outcomes Following AVD-104 Treatment for Geographic Atrophy.

Nathan N Macha1,2, Minzhong Yu3, Sheeraz Naqvi2

  • 1Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.

Journal of Vitreoretinal Diseases
|July 6, 2026
PubMed
Summary

AVD-104 treatment showed potential benefits for geographic atrophy (GA) in dry age-related macular degeneration (AMD). Multifocal electroretinography (mfERG) indicated retinal function recovery in the junctional zone two months post-treatment.

Keywords:
AVD-104age-related macular degenerationcomplement inhibitorgeographic atrophymultifocal electroretinography

Related Experiment Videos

Last Updated: Jul 7, 2026

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Clinical Trials

Background:

  • Dry age-related macular degeneration (AMD) with geographic atrophy (GA) is a leading cause of vision loss.
  • Current treatments for dry AMD are limited, highlighting the need for novel therapeutic strategies.
  • Assessing functional endpoints like mfERG is crucial for evaluating treatment efficacy in dry AMD.

Purpose of the Study:

  • To evaluate the treatment effect of AVD-104 in patients with GA secondary to dry AMD.
  • To assess the utility of multifocal electroretinography (mfERG) as a clinical endpoint for dry AMD studies.
  • To determine the safety and efficacy of intravitreal AVD-104 in a phase 2/3 clinical trial.

Main Methods:

  • Prospective case series of 6 patients with advanced bilateral GA.
  • Single intravitreal injection of AVD-104 in the study eye.
  • mfERG and best-corrected visual acuity (BCVA) measurements at baseline and follow-up visits (months 1, 2, and 3).

Main Results:

  • AVD-104 treatment led to significant improvements in retinal function, particularly in the junctional zone (40.1% gain in N1-P1 response density at month 2).
  • Five out of six eyes showed >20% gain in junctional N1-P1 response density at month 2, with three maintaining this at month 3.
  • Mean BCVA improved by +6.0 letters over baseline at month 3, indicating a positive treatment effect.

Conclusions:

  • AVD-104 demonstrated a beneficial treatment effect in eyes with GA secondary to dry AMD.
  • mfERG measurements supported the recovery of retinal function in the junctional zone two months after AVD-104 treatment.
  • mfERG shows promise as a sensitive clinical endpoint for evaluating functional recovery in dry AMD clinical trials.